Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Basal Cell × Chemoprevention × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Dysplasia 1 Squamous Intraepithelial Lesions 1 Carcinoma, Basal Cell 1

Interventions

HhAntag691 13 Aminolevulinic Acid 5 sonidegib 4 Nivolumab 3 tazarotene 2 daromun 2 cemiplimab 2 Specimen Handling 2 Radiotherapy 2 IPI-926 2 Drug Evaluation 2 Celecoxib 2 3-ingenyl angelate 2 talimogene laherparepvec 1 remetinostat 1 relatlimab 1 endonuclease V, phage T4 1 Triamcinolone 1 Sutures 1 Surgical Procedures, Operative 1 Solutions 1 Papillomavirus Vaccines 1 Opdualag 1 Niacinamide 1 NVP-BKM120 1 Methotrexate 1 Magnetic Resonance Spectroscopy 1 Lighting 1 Ipilimumab 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡